أعرض في EDS

Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients

التفاصيل البيبلوغرافية
العنوان: Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients
المؤلفون: Kei Ikeda, Mitsuhiro Iwahashi, Toshihide Mimura, Michi Tanaka, Takahiro Okazaki, Tetsuo Kubota, Kazuyoshi Saito, Fumikazu Sakai, Yasushi Nawata, Motohide Kaneko, Shigemasa Sawada, Masaya Mukai, Yoshihiro Matsukawa, Takenobu Iso, Yukiko Komano, Mitsuru Motegi, Yoshiya Tanaka, Takashi Kuroiwa, Hitoshi Tokuda, Atsushi Ogata, Kaori Watanabe, Yuji Akiyama, Ryoko Sakai, Kazuko Shiozawa, Toshihiro Nanki, Haruhito Sugiyama, Masayoshi Harigai, Hiroshi Nakajima, Hirotaka Kodama, Shoji Sugii, Ryuji Koike, Nobuyuki Miyasaka, Hirofumi Taki
المصدر: Modern rheumatology. 23(6)
سنة النشر: 2012
مصطلحات موضوعية: musculoskeletal diseases, Male, medicine.medical_specialty, Prednisolone, Antibodies, Monoclonal, Humanized, Pneumocystis carinii, Arthritis, Rheumatoid, Rheumatology, Risk Factors, Internal medicine, parasitic diseases, Adalimumab, medicine, Humans, In patient, skin and connective tissue diseases, Aged, Retrospective Studies, Retrospective review, business.industry, Pneumonia, Pneumocystis, Pneumocystis jirovecii Pneumonia, Case-control study, Middle Aged, medicine.disease, respiratory tract diseases, Surgery, Methotrexate, Rheumatoid arthritis, Antirheumatic Agents, Case-Control Studies, Drug Therapy, Combination, Female, business, medicine.drug
الوصف: To investigate the clinical characteristics and risk factors of Pneumocystis jirovecii pneumonia (PCP) in rheumatoid arthritis (RA) patients treated with adalimumab.We conducted a multicenter, retrospective, case-control study to compare RA patients treated with adalimumab with and without PCP. Data from 17 RA patients who were diagnosed with PCP and from 89 RA patients who did not develop PCP during adalimumab treatment were collected.For the PCP patients, the median age was 68 years old, with a median RA disease duration of eight years. The median length of time from the first adalimumab injection to the development of PCP was 12 weeks. At the onset of PCP, the median dosages of prednisolone and methotrexate were 5.0 mg/day and 8.0 mg/week, respectively. The patients with PCP were significantly older (p0.05) and had more structural changes (p0.05) than the patients without PCP. Computed tomography of the chest revealed ground-glass opacity without interlobular septal boundaries in the majority of the patients with PCP. Three PCP patients died.PCP may occur early in the course of adalimumab therapy in patients with RA. Careful monitoring, early diagnosis, and proper management are mandatory to secure a good prognosis for these patients.
تدمد: 1439-7609
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cccbf59fb37f9d7e8729eb7ee870f254
https://pubmed.ncbi.nlm.nih.gov/23212592
رقم الأكسشن: edsair.doi.dedup.....cccbf59fb37f9d7e8729eb7ee870f254
قاعدة البيانات: OpenAIRE
الوصف
تدمد:14397609